Vera Therapeutics filings document a Nasdaq-listed biotechnology company developing atacicept for serious immunological diseases, including IgA nephropathy. Form 8-K reports provide financial results, corporate updates, clinical and regulatory disclosures for the atacicept program, and material governance events such as board appointments, executive changes, and compensatory arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, advisory executive compensation votes, board committee structure, and related governance practices. The company’s filings also identify its Class A common stock registered on The Nasdaq Stock Market and disclose equity awards issued under director compensation and inducement grant arrangements.
Vera Therapeutics Inc ownership disclosure: The Vanguard Group amended its Schedule 13G to report 0 shares beneficially owned of Vera Therapeutics common stock, representing 0% of the class, following an internal realignment.
The filing states that on January 12, 2026 Vanguard reorganized and certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim on 03/27/2026.
Vera Therapeutics Chief Legal Officer Jane Wright-Mitchell received new equity awards. She was granted a stock option for 56,850 shares of Class A Common Stock at an exercise price of $40.73 per share, expiring on March 22, 2036.
She also received 42,403 restricted stock units under the 2024 Inducement Plan, representing 42,403 shares of Class A Common Stock. According to the vesting terms, one-fourth of the RSUs vest on each of May 20, 2027, 2028, 2029 and 2030, while the option vests 12/48ths on March 23, 2027 and 1/48th monthly thereafter, in each case contingent on continued service.
Vera Therapeutics, Inc. filed an initial insider ownership report for Chief Legal Officer Jane Wright-Mitchell. This Form 3 establishes her status as an officer subject to insider reporting rules. The structured data provided shows no insider share transactions or derivative holdings reported in this filing.
Vera Therapeutics, Inc. senior vice president of finance and chief accounting officer Joseph R. Young exercised stock options to acquire 10,000 shares of Class A common stock at an exercise price of $3.9396 per share on March 13, 2026.
Following the transactions, he directly owns 75,754 shares of Class A common stock and holds 38,589 stock options. The filing notes that 1,032 of his shares were acquired through the company’s 2021 Employee Stock Purchase Plan, and the option grant vests over time, with a portion vesting monthly.
Vera Therapeutics reports a Schedule 13G filing showing Deep Track-affiliated holders beneficially own 3,921,362 shares of Class A common stock. That holding represents 5.50% of the class based on 71,355,667 shares outstanding as of February 23, 2026.
The filing lists Deep Track Capital, LP and Deep Track Biotechnology Master Fund, Ltd., with shared voting and dispositive power over the 3,921,362 shares, and identifies David Kroin as a control person for the Deep Track entities.
Vera Therapeutics reported that its board appointed Christopher Hite as a Class III director effective March 5, 2026, with his initial term running until the 2027 annual stockholders’ meeting. His compensation follows the company’s non-employee director policy.
On joining the board, Hite received a nonstatutory stock option to purchase 24,937 shares of Class A common stock at an exercise price of $38.85 per share. The option vests monthly over three years, subject to his continued service. He will also receive an annual cash retainer of $45,000, pro-rated for 2026.
Beginning with the 2027 annual meeting, Hite will be eligible each year for an option to buy up to the lesser of 18,000 shares or the number of shares with a grant date fair value not above $400,000, vesting by the next annual meeting or one year from grant. He will sign the company’s standard indemnification agreement, and the company notes there were no special arrangements or related-person transactions tied to his selection.
Vera Therapeutics director receives stock option grant
Vera Therapeutics director Christopher Hite was granted an option to buy 24,937 shares of the company’s stock at an exercise price of $0.00 per share. The option vests monthly over three years, as long as he continues serving the company.
Vera Therapeutics, Inc. director Christopher Hite filed an initial ownership report on Form 3. The data provided lists him as a director of the company and shows no reportable stock transactions or holdings in the transaction section of the filing.
Sofinnova Venture Partners X and related entities now report owning less than 5% of Vera Therapeutics’ Class A common stock. They beneficially own 2,793,987 shares, representing 3.9% of the company, based on 71,355,667 shares outstanding as of February 23, 2026.
The group’s ownership fell below the 5% threshold as of September 30, 2025, primarily because Vera Therapeutics sold additional shares over time. Venture investor Sofinnova characterizes its position as held for investment purposes and may buy more, sell, or distribute shares depending on market conditions and company developments.
Vera Therapeutics is a late clinical-stage biotech focused on serious immunological kidney diseases, led by atacicept for IgA nephropathy (IgAN). In a pivotal Phase 3 trial, atacicept achieved a 46% reduction in proteinuria (UPCR) from baseline and a 42% reduction versus placebo at week 36 (p<0.0001), with a safety profile generally comparable to placebo and fewer serious adverse events.
The company has filed a Biologics License Application for atacicept in IgAN, which received FDA priority review with a PDUFA target action date of July 7, 2026. Vera is also advancing atacicept in other autoimmune kidney diseases through the ORIGIN EXTEND and PIONEER studies, MAU868 for BK virus in kidney transplant recipients, and VT-109, a next‑generation dual BAFF/APRIL inhibitor, all supported by a broad global IP and licensing strategy.